Patient and physician treatment preferences in resectable non-small cell lung cancer
Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments
This project will see which approved treatments people with resectable stage II–IIIB NSCLC and their treating doctors prefer and why.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 55 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Locations | 1 site (London) |
| Trial ID | NCT06448793 on ClinicalTrials.gov |
What this trial studies
This observational project collects treatment preferences from adults with resectable stage II–IIIB NSCLC and the physicians who treat them across the US, Germany, and Japan. Participants will complete structured interviews or surveys about approved NSCLC therapies and the trade-offs they consider when choosing treatments. Physician participants include medical oncologists, pulmonologists, thoracic surgeons, and radiologists who have treated at least three new resectable NSCLC patients in the past year. Responses will be analyzed to identify common preference patterns and factors that influence decision making in the resectable NSCLC setting.
Who should consider this trial
Good fit: Ideal candidates are adults (≥18) with resectable stage II–IIIB NSCLC who live in the US, Germany, or Japan, can read and speak English, German, or Japanese, and can give informed consent for interviews.
Not a fit: Patients with cognitive or sensory impairments that prevent informed consent or participation, those with another active malignancy, or those unwilling to be audio-recorded or who do not have resectable NSCLC are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, the findings could help align treatment choices with patient priorities and support better shared decision-making between patients and clinicians.
How similar studies have performed: Preference and qualitative studies have been used in oncology to inform guidelines and drug development, so the approach is established even if specific work on resectable NSCLC is less common.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients * Aged ≥18 years at the time of enrollment in the study * Resident of the US, Germany, or Japan * Able to read, speak, and understand English, German or Japanese * Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC) Physicians * Resident of the US, Germany, or Japan * Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology * Treated at least three new patients with resectable NSCLC in the past year Exclusion Criteria: Patients * Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment) * Being diagnosed with another malignancy alongside NSCLC * Not willing to be audio-recorded during the interview Physicians * Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment) * Not willing to be audio-recorded during the interview
Where this trial is running
London
- Evidera — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.